The burden of noncommunicable disease in South Africa

August 24, 2009

The fourth paper focuses on the emerging chronic diseases epidemic in SA, and is written by Professor Bongani Mayosi, Groote Schuur Hospital, Cape Town, SA, and colleagues. They urge the launching of a national initiative to establish sites of service excellence in urban and rural settings throughout South Africa to trial, assess, and implement integrated care interventions for chronic infectious and non-communicable diseases.

The authors say: "Evidence of a rise in mortality and morbidity from non-communicable diseases in all strata of South African society is compelling. These findings represent the most advanced end of the range of rural and urban sub-Saharan transitions. Further, there is good evidence regarding the rise of vascular disorders--including hypertension, stroke, and ischaemic heart disease--elsewhere in east and west Africa, suggesting that complex health transitions are underway in several settings. The widely held perception that the burden of disease in sub-Saharan Africa is composed largely of communicable diseases is thus flawed."

The number of people aged 60 or over (7.3% at 2001 census) is likely to treble between now and 2025, which will in turn result in a doubling of cardiovascular deaths by 2040. The rising burden of non-communicable diseases is shown by an increasing number of deaths from diabetes, chronic kidney disease, and cancer of the prostate and cervix, and by the increasing proportion of disability-adjusted life years attributed to neuropsychiatric disorders. The burden of these diseases will probably increase as the roll-out of antiretroviral therapy takes effect and reduces mortality from HIV/AIDS.

The authors conclude: "The scale of the challenge posed by the combined and growing burden of HIV/AIDS and non-communicable diseases demands an extraordinary response that South Africa is well able to provide. Concerted action is needed to strengthen the district-based primary health-care system, to integrate the care of chronic diseases and management of risk factors, to develop a national surveillance system, and to apply interventions of proven cost-effectiveness in the primary and secondary prevention of such diseases within populations and health services."
-end-
Professor Bongani Mayosi, Groote Schuur Hospital, Cape Town, SA T) +27-21-406-6200 /+27-21-531-0388 /+27-82-372-7655 E) Bongani.Mayosi@uct.ac.za

Full paper 4: http://press.thelancet.com/saser4.pdf

Lancet

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.